Display options
Cite
Wagner CR, Iyer VV, McIntee EJ. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev. 2000;20(6):417-51doi: 10.1002/1098-1128(200011)20:6<417::aid-med1>3.0.co;2-z.
Wagner, C. R., Iyer, V. V., & McIntee, E. J. (2000). Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Medicinal research reviews, 20(6), 417-51. https://doi.org/10.1002/1098-1128(200011)20:6<417::aid-med1>3.0.co;2-z
Wagner, C R, et al. "Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides." Medicinal research reviews vol. 20,6 (2000): 417-51. doi: https://doi.org/10.1002/1098-1128(200011)20:6<417::aid-med1>3.0.co;2-z
Wagner CR, Iyer VV, McIntee EJ. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev. 2000 Nov;20(6):417-51. doi: 10.1002/1098-1128(200011)20:6<417::aid-med1>3.0.co;2-z. PMID: 11058891.
Copy Download .nbib Format: NLM
Share it on

Med Res Rev. 2000 Nov;20(6):417-51. doi: 10.1002/1098-1128(200011)20:6<417::aid-med1>3.0.co;2-z.

Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides.

Medicinal research reviews

C R Wagner, V V Iyer, E J McIntee

Affiliations

  1. Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.

PMID: 11058891 DOI: 10.1002/1098-1128(200011)20:6<417::aid-med1>3.0.co;2-z

Abstract

To overcome the many hurdles preventing the use of antiviral and anticancer nucleosides as therapeutics, the development of a prodrug methodology (i.e., pronucleotide) for the in vivo delivery of nucleotides has been proposed as a solution. The ideal pronucleotide should be non-toxic, stable in plasma and blood, capable of being i. v. and/or orally dosed, and intracellularly convertible to the corresponding nucleotide. Although this goal has yet to be achieved, many clever and imaginative pronucleotide approaches have been developed, which are likely to be important pharmacological tools. This review will discuss the major advances and future directions of the emerging field of antiviral and anticancer pronucleotide design and development.

Substances

MeSH terms

Publication Types